Disc Medicine, Inc./$IRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Disc Medicine, Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Ticker
$IRON
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
94
ISIN
US2546041011
Website
IRON Metrics
BasicAdvanced
$1.7B
-
-$3.92
2.78
-
Price and volume
Market cap
$1.7B
Beta
2.78
52-week high
$57.19
52-week low
$30.82
Average daily volume
375K
Financial strength
Current ratio
37.65
Quick ratio
37.066
Long term debt to equity
4.568
Total debt to equity
4.64
Interest coverage (TTM)
-94.08%
Profitability
EBITDA (TTM)
-138.054
Effective tax rate (TTM)
-0.40%
Management effectiveness
Return on assets (TTM)
-16.24%
Return on equity (TTM)
-23.34%
Valuation
Price to book
2.62
Price to tangible book (TTM)
2.62
Price to free cash flow (TTM)
-14.461
Free cash flow yield (TTM)
-6.91%
Free cash flow per share (TTM)
-346.37%
Growth
Earnings per share change (TTM)
15.59%
3-year earnings per share growth (CAGR)
-53.83%
Bulls say / Bears say
Disc Medicine's cash position of $694.7 million as of March 31, 2025, is expected to fund operations into 2028, providing financial stability for ongoing and future projects. (ir.discmedicine.com)
The company plans to submit a New Drug Application (NDA) for bitopertin in erythropoietic protoporphyria (EPP) in the second half of 2025 under the accelerated approval pathway, potentially leading to earlier market entry. (ir.discmedicine.com)
Disc Medicine secured a $200 million non-dilutive debt financing deal in November 2024, enhancing financial flexibility without shareholder dilution. (ir.discmedicine.com)
The company reported a net loss of $34.1 million for Q1 2025, an increase from $26.9 million in Q1 2024, indicating rising operational costs. (ir.discmedicine.com)
Despite positive data, bitopertin's Phase 2 AURORA study did not meet all secondary endpoints related to light tolerance, which could impact its perceived efficacy. (ir.discmedicine.com)
The success of Disc Medicine's pipeline heavily relies on regulatory approvals and successful commercialization, both of which carry inherent uncertainties and risks. (ir.discmedicine.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IRON News
AllArticlesVideos
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
GlobeNewsWire·1 week ago
Disc Medicine to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 weeks ago
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Disc Medicine, Inc. stock?
Disc Medicine, Inc. (IRON) has a market cap of $1.7B as of June 20, 2025.
What is the P/E ratio for Disc Medicine, Inc. stock?
The price to earnings (P/E) ratio for Disc Medicine, Inc. (IRON) stock is 0 as of June 20, 2025.
Does Disc Medicine, Inc. stock pay dividends?
No, Disc Medicine, Inc. (IRON) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Disc Medicine, Inc. dividend payment date?
Disc Medicine, Inc. (IRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Disc Medicine, Inc.?
Disc Medicine, Inc. (IRON) has a beta rating of 2.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.